Wall Street Zen Upgrades OnKure Therapeutics (NASDAQ:OKUR) to Hold

OnKure Therapeutics (NASDAQ:OKUR) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OnKure Therapeutics has an average rating of “Hold” and an average target price of $34.00.

OnKure Therapeutics Stock Up 7.4%

OKUR stock opened at $3.78 on Friday. OnKure Therapeutics has a twelve month low of $1.70 and a twelve month high of $5.28. The stock has a market cap of $51.22 million, a P/E ratio of -0.86 and a beta of 0.45. The business’s 50-day moving average price is $2.84 and its 200-day moving average price is $2.87.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.16. On average, equities research analysts expect that OnKure Therapeutics will post -4.05 earnings per share for the current fiscal year.

Institutional Trading of OnKure Therapeutics

Several institutional investors have recently made changes to their positions in OKUR. XTX Topco Ltd purchased a new position in OnKure Therapeutics in the 2nd quarter worth approximately $25,000. Bailard Inc. purchased a new stake in OnKure Therapeutics during the 2nd quarter valued at approximately $34,000. Jane Street Group LLC bought a new stake in shares of OnKure Therapeutics during the fourth quarter valued at approximately $56,000. Barclays PLC raised its position in shares of OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after buying an additional 26,621 shares during the last quarter. Finally, Rangeley Capital LLC purchased a new position in shares of OnKure Therapeutics in the second quarter worth $71,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.